{"id":"NCT01323478","sponsor":"H. Lundbeck A/S","briefTitle":"Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults","officialTitle":"A Long-term, Open-label, Flexible-dose, Extension Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 (15 and 20 mg/Day) in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04","primaryCompletion":"2012-09","completion":"2012-10","firstPosted":"2011-03-25","resultsPosted":"2014-02-11","lastUpdate":"2014-02-11"},"enrollment":71,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Vortioxetine (Lu AA21004)","otherNames":["Brintellix"]}],"arms":[{"label":"Vortioxetine","type":"EXPERIMENTAL"}],"summary":"To evaluate the long-term safety and tolerability of flexible doses, 15 and 20 mg/day, of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD)","primaryOutcome":{"measure":"Number of Patients With Adverse Events (AEs)","timeFrame":"Baseline to end of the 4-week safety follow-up period","effectByArm":[{"arm":"Vortioxetine 15 or 20 mg/Day","deltaMin":56,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["36884024"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":71},"commonTop":["Nausea","Dizziness","Headache","Nasopharyngitis","Insomnia"]}}